GROUP ONE TRADING, L.P. - CELLDEX THERAPEUTICS INC NEW ownership

CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 84 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2018. The put-call ratio across all filers is - and the average weighting 1.2%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of CELLDEX THERAPEUTICS INC NEW
ValueSharesWeighting
Q4 2018$2,000
-85.7%
10,980
-63.7%
0.00%
Q3 2018$14,000
-66.7%
30,212
-63.4%
0.00%
Q2 2018$42,000
-69.6%
82,530
+39.6%
0.00%
-100.0%
Q1 2018$138,000
-29.6%
59,120
-14.4%
0.00%0.0%
Q4 2017$196,000
+29.8%
69,044
+30.9%
0.00%0.0%
Q3 2017$151,000
+39.8%
52,735
+21.1%
0.00%0.0%
Q2 2017$108,000
-64.7%
43,534
-48.7%
0.00%
-75.0%
Q1 2017$306,000
-37.7%
84,846
-38.9%
0.00%
-20.0%
Q4 2016$491,000
-10.9%
138,795
+1.8%
0.01%
-16.7%
Q3 2016$551,000
-24.0%
136,328
-17.5%
0.01%
-33.3%
Q2 2016$725,000
+88.8%
165,218
+62.5%
0.01%
+80.0%
Q1 2016$384,000
-94.6%
101,654
-77.7%
0.01%
-94.0%
Q4 2015$7,139,000
+8.0%
455,263
-27.4%
0.08%
-7.7%
Q3 2015$6,612,000
-3.8%
627,278
+130.3%
0.09%
-5.2%
Q2 2015$6,870,000
-25.9%
272,391
-18.1%
0.10%
-34.2%
Q1 2015$9,270,000
+172.6%
332,609
+78.5%
0.15%
+186.3%
Q4 2014$3,401,000
+83.4%
186,382
+30.3%
0.05%
+75.9%
Q3 2014$1,854,000
-47.0%
143,020
-33.3%
0.03%
-46.3%
Q2 2014$3,497,000
-9.9%
214,272
-2.5%
0.05%
-16.9%
Q1 2014$3,883,000
-26.1%
219,769
+1.2%
0.06%
-17.7%
Q4 2013$5,256,000
+27.3%
217,083
+86.2%
0.08%0.0%
Q3 2013$4,130,000
+253.9%
116,555
+55.9%
0.08%
+172.4%
Q2 2013$1,167,00074,7510.03%
Other shareholders
CELLDEX THERAPEUTICS INC NEW shareholders Q4 2018
NameSharesValueWeighting ↓
Ridgeback Capital Investments L.P. 1,025,000$24,815,00031.36%
TSP Capital Management Group, LLC 836,342$20,248,0008.80%
Iguana Healthcare Management, LLC 200,000$4,842,0002.76%
First Light Asset Management, LLC 116,096$2,811,0002.38%
SECTORAL ASSET MANAGEMENT INC 2,227,688$53,932,0002.33%
BENNETT LAWRENCE MANAGEMENT L L C/NY 550,735$13,334,0002.05%
Eventide Asset Management 257,000$6,222,0001.92%
Redmile Group, LLC 397,951$9,634,0001.19%
ARDSLEY ADVISORY PARTNERS LP 357,000$8,643,0001.15%
Rhenman & Partners Asset Management AB 90,000$2,179,0000.85%
View complete list of CELLDEX THERAPEUTICS INC NEW shareholders